Allison Bratzel
Stock Analyst at Piper Sandler
(1.78)
# 1269
Out of 5,270 analysts
35
Total ratings
56.00%
Success rate
21.36%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
enGene Holdings | Initiates Coverage On: Overweight | 26 | 5.85 | 344.44% | 1 | Feb 18, 2025 | |
argenx | Maintains: Overweight | 620 725 | 622.66 | 16.44% | 13 | Jan 7, 2025 | |
Travere Therapeutics | Maintains: Neutral | 12 22 | 19.75 | 11.39% | 2 | Nov 14, 2024 | |
Rigel Pharmaceutical... | Maintains: Neutral | 15 23 | 22.34 | 2.95% | 2 | Nov 14, 2024 | |
Ionis Pharmaceutical... | Maintains: Overweight | 65 62 | 32.54 | 90.53% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 36.24 | 15.89% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 10.15 | 116.75% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 3.06 | 30.72% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 5.13 | 289.86% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.35 | 751.06% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 44 | 12.1 | 263.64% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 70.18 | 42.49% | 2 | Feb 8, 2023 |